Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $402.5852W HIGH $560.25
Volume
1.49 M
Value Traded
1.42 B
Short % Float
1.87%
-0.29%Week
-3.43%1 Month
+3.68%3 Month
+15.35%6 Month
+99.97%5 Year
+9,556%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
127.73 B
EPS (TTM)
17.38
P/E Ratio
28.96
Ent. Value
114.09 B
Total Shares
253.83 M
Float Shares
252.88 M
Insiders
0.23%
Institutions
98.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
VRTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Vertex Pharmaceuticals Incorporated
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vertex Pharmaceuticals Incorporated
494Total events
23Upcoming
194Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutInaxaplinClinical Data
Vertex announces positive Phase 2b AMPLIFIED results of inaxaplin in AMKD with modest proteinuria and AMKD with type 2 diabetes
APOL1-mediated kidney disease (AMKD) with modest proteinuria and AMKD with type 2 diabetessource ↗
▲Enrollment CompleteInaxaplinTrial
Vertex completes full enrollment in Phase 2/3 AMPLITUDE trial of inaxaplin in AMKD
APOL1-mediated kidney disease (AMKD)source ↗
▲Primary Endpoint MetInaxaplinClinical Data
Inaxaplin met primary endpoint in AMPLIFIED cohort 1 (AMKD with modest proteinuria), -42.7% UACR at Week 13
APOL1-mediated kidney disease (AMKD) with modest proteinuriasource ↗
▲Partnership / LicenseCorporate
Vertex partnered with Lindsey Vonn to raise awareness of JOURNAVX
●R&D DayPresentation
Vertex CEO fireside chat at Morgan Stanley 24th Annual Global Healthcare Conference
●R&D DayPresentation
Vertex management fireside chat at 2026 Cantor Global Healthcare Conference
●R&D DayPresentation
Vertex management fireside chat at Wells Fargo 21st Annual Healthcare Conference
▲Product LaunchJournavxApprovedPost-Market
JOURNAVX prescribed to over one million Americans since approval
moderate-to-severe acute painsource ↗
▲EU MAA SubmissionPALSONIFYEx-US Regulatory
EMA approval of PALSONIFY (paltusotine) for acromegaly
acromegalysource ↗
◆Trial InitiationatumelnantTrial
Phase 1/2b trial in ADCS currently enrolling patients
ACTH-dependent Cushing's syndromesource ↗
◆Trial InitiationpaltusotineTrial
Phase 3 clinical development for carcinoid syndrome
carcinoid syndrome associated with neuroendocrine tumorssource ↗
▲FDA ApprovalCasgevyApprovedFDA Decision
US FDA approval for expanded use of CASGEVY in patients ages 2 years and older with sickle cell disease or transfusion-dependent beta thalassemia
sickle cell disease or transfusion-dependent beta thalassemiasource ↗
◆Oral PresentationCasgevyApprovedPresentation
First European presentation of data in children ages 5–11 at EHA Congress
sickle cell disease and beta thalassemiasource ↗
◆Other Regulator MilestoneCasgevyApprovedEx-US Regulatory
Additional global regulatory submissions announced
sickle cell disease and beta thalassemiasource ↗
◆Oral PresentationPresentation
Vertex to participate in Goldman Sachs 47th Annual Global Healthcare Conference
◆Oral PresentationAlyftrekApprovedPresentation
Vertex Presents New Data on ALYFTREK at European Cystic Fibrosis Conference
cystic fibrosissource ↗
●BLA SubmissionPovetaciceptFiledRegulatory Filing
BLA submission for accelerated approval of Povetacicept in IgA Nephropathy
IgA Nephropathysource ↗
▲FDA Filing AcceptedPovetaciceptFiledRegulatory Filing
FDA acceptance of BLA filing for Povetacicept in IgA Nephropathy
IgA Nephropathysource ↗
▲Other Regulator MilestoneCasgevyApprovedEx-US Regulatory
Reimbursement agreement signed with GKV-Spitzenverband in Germany
sickle cell disease and transfusion-dependent beta thalassemiasource ↗
▲Reimbursement / PricingCasgevyApprovedPost-Market
CASGEVY reimbursement agreement signed in Germany with GKV-Spitzenverband
Sickle Cell Disease and Transfusion-Dependent Beta Thalassemiasource ↗
●BLA SubmissionPovetaciceptFiledRegulatory Filing
Completed rolling biologics application for povetacicept in IgAN
IgA nephropathy (IgAN)source ↗
◆Oral PresentationPresentation
Vertex management to participate in upcoming May 2026 investor conferences
▲Reimbursement / PricingCasgevyApprovedPost-Market
Vertex secured reimbursement for CASGEVY in Germany for eligible patients 12 years and older
severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)source ↗
▲Label ExpansionAlyftrekApprovedFDA Decision
FDA approval for label expansion of ALYFTREK to ages 6 and older with responsive CFTR variants
cystic fibrosissource ↗
▲Label ExpansionTrikaftaApprovedFDA Decision
FDA approval for label expansion of TRIKAFTA to ages 6 and older with responsive CFTR variants
cystic fibrosissource ↗
◆Topline ReadoutWVE-007Clinical Data
Results from 400 mg cohort and three-month follow-up data from 600 mg cohort of WVE-007
obesitysource ↗
▲Reimbursement / PricingAlyftrekApprovedPost-Market
Vertex secured reimbursement for ALYFTREK in four additional countries, including Spain
Cystic Fibrosis (CF)source ↗
▲Reimbursement / PricingJournavxApprovedPost-Market
Vertex reached agreements with two additional major PBMs for Medicare Part D coverage of JOURNAVX
moderate-to-severe acute painsource ↗
▲FDA Filing AcceptedSuzetrigineApprovedRegulatory Filing
Health Canada accepted Vertex's new drug submission for suzetrigine for moderate-to-severe acute pain
moderate-to-severe acute painsource ↗
◆Oral PresentationPresentation
Vertex management participation in TD Cowen 46th Annual Health Care Conference fireside chat
▲Topline ReadoutPovetaciceptFiledClinical Data
Topline Phase 3 data for povetacicept in IgAN
IgA nephropathy (IgAN)source ↗
▲Primary Endpoint MetPovetaciceptFiledClinical Data
Primary endpoint met in RAINIER trial
IgA nephropathy (IgAN)source ↗
▲Secondary Endpoint DataPovetaciceptFiledClinical Data
Key secondary endpoint met in RAINIER trial
IgA nephropathy (IgAN)source ↗
◆Topline ReadoutremternetugClinical Data
Top-line Phase III data from TRAILRUNNER-ALZ 1 study of remternetug
Alzheimer's diseasesource ↗
▲BLA SubmissionPovetaciceptFiledRegulatory Filing
Completed rolling BLA submission for U.S. accelerated approval
IgA nephropathysource ↗
▲Interim AnalysisPovetaciceptFiledTrial
Positive Week 36 interim analysis results for primary and all secondary endpoints
IgA nephropathysource ↗
●Quarterly UpdateCasgevyApprovedCorporate
Vertex full-year 2025 earnings report: 64 patients infused with Casgevy in 2025
sickle cell disease and transfusion-dependent beta thalassemiasource ↗
▲PRV GrantedCasgevyApprovedDesignation
Vertex received a Commissioner's National Priority Review Voucher for Casgevy label expansion
sickle cell disease in children aged 5 to 11source ↗
▲Partnership / LicenseCorporate
Vertex and WuXi Biologics sign license and research service agreement for trispecific T-cell engager
B-cell mediated autoimmune diseasessource ↗
Past FDA Catalysts and PDUFA Decisions
How VRTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-04-01 | Trikafta (elexacaftor, ivacaftor, tezacaftor) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B79 / 100
Pipeline Score
$22.0B
Pipeline Value
$53.4B
Commercial Value
Overvalued
Valuation Signal
28
Drugs Scored
0.3x
rNPV / MCap
Top 3%
Large Pharma(rank 21 of 658)
Percentile Rank
Vertex Pharmaceuticals Incorporated holds a solid B-grade pipeline (79/100), with $22.0B risk-adjusted pipeline value, led by VX-880 in Diabetes Mellitus, Type 1 (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $12.6B x 4.2 = $53.4B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| TRIKAFTA/KAFTRIO | $10.1B | $10.4B | -3% |
| ALYFTREK | $1.6B | - | - |
| CASGEVY | $191M | $55M | +248.9% |
| JOURNAVX | $125M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VX-880 Monoclonal antibodyNCT04786262 | Diabetes Mellitus, Type 1 | Phase 3 | RECRUITING | 57 | Dec 31, 2031 |
Clinical Trial Results
Readouts, endpoints and source filings for every VRTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| inaxaplin | APOL1-mediated kidney disease | Phase 2b | 2026-09-22 | cohort 1: UACR reduction -42.7%, UPCR reduction -44.7%; cohort 2: UACR reduction -17.3%, UPCR reduction -25.4%Read More | Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE TrialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SACHS BRUCE IDirector | Grant/Award | 99.941 15,771.807 held | $475.28 | 07/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VRTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 12.3 % (51.9 %) | 100.23 M | 201.79 K | 56.05% ( 72.48 K) |
VRTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VRTX ranks across every disease it competes in
Competitive Position is a premium feature
See how VRTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVRTX News
VRTX▼ -0.5%today
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
Vertex Pharmaceuticals will announce its third quarter 2026 financial results on November 2, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET, providing investors with insights into the company's performance. Access details for the call are provided for both U.S. and international participants.
Read more →VRTXVertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
Vertex Pharmaceuticals announced positive results from the Phase 2b AMPLIFIED study of inaxaplin for APOL1-mediated kidney disease. The study demonstrated significant reductions in urine albumin to creatinine ratio (UACR) in patients with modest proteinuria and those with type 2 diabetes. Vertex has completed enrollment in the Phase 2/3 AMPLITUDE trial, with interim analysis results expected in early 2027, which could support accelerated approval in the U.S.
Read more →VRTXVertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals has teamed up with champion skier Lindsey Vonn to promote JOURNAVX, a non-opioid medication approved for treating moderate-to-severe acute pain. This partnership aims to raise awareness about the first new class of pain medicine in over two decades. JOURNAVX was approved by the FDA in January 2025.
Read more →VRTXVertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
Vertex Pharmaceuticals has successfully completed its acquisition of Crinetics Pharmaceuticals, a company specializing in therapeutics for endocrine diseases. This acquisition is part of Vertex's strategy to diversify and grow its portfolio. Additionally, the company has expanded its executive leadership team to better support its ongoing development and expansion efforts.
Read more →VRTXVertex to Participate in Upcoming September Investor Conferences
Vertex Pharmaceuticals has announced its participation in four upcoming investor conferences, highlighting its commitment to investor engagement. Senior Vice President Susie Lisa and Executive Director Manisha Pai will lead discussions at notable events, including the Wells Fargo 21st Annual Healthcare Conference. This proactive approach reflects the company's transparency and confidence in its future.
Read more →VRTXVertex Reports Second Quarter 2026 Financial Results
Vertex Pharmaceuticals reported strong financial results for Q2 2026, highlighting significant revenue growth in cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain. The company also updated its full-year revenue guidance positively. Additionally, the pending acquisition of Crinetics will expand its focus to rare endocrine diseases.
Read more →VRTXVertex to Announce Second Quarter 2026 Financial Results on August 3rd
Vertex Pharmaceuticals is set to announce its financial results for the second quarter of 2026 on August 3rd. This announcement is part of the company's regular financial reporting schedule. Details regarding the performance and outlook will likely be discussed during the announcement.
Read more →VRTXVertex to Acquire Crinetics Pharmaceuticals
Vertex Pharmaceuticals has announced its intention to acquire Crinetics Pharmaceuticals. The acquisition aims to enhance Vertex's portfolio and capabilities in the biopharmaceutical sector. Further details regarding the financial aspects and strategic implications of the acquisition have yet to be disclosed.
Read more →VRTX▲ +6%on this newsshared move
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Vertex has received FDA approval for the expanded use of CASGEVY® in treating individuals aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia. This approval represents a significant milestone in providing effective treatment options for these conditions. The decision is expected to enhance patient care and outcomes.
Read more →VRTXVertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
Vertex Pharmaceuticals presented new data on CASGEVY® at the European Hematology Association Congress. This included the first European presentation of data in children aged 5-11. Additionally, the company announced further global regulatory submissions related to CASGEVY®.
Read more →VRTXVertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
Vertex Pharmaceuticals presented new data on ALYFTREK® at the European Cystic Fibrosis Conference. The details of the findings were not disclosed in the article. The presentation is expected to contribute to ongoing discussions about cystic fibrosis treatments.
Read more →VRTXVertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
Vertex Pharmaceuticals will participate in the Goldman Sachs 47th Annual Global Healthcare Conference scheduled for June 10. This event is a significant platform for the company to engage with investors and discuss its strategic initiatives. Further details about the participation are yet to be disclosed.
Read more →VRTXVertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
Vertex Pharmaceuticals announced that the U.S. FDA has accepted its Biologics License Application for Povetacicept, aimed at treating IgA Nephropathy. This acceptance is a crucial step towards potential accelerated approval, which may enhance patient access to this innovative therapy. The company is optimistic about the drug's prospects in addressing this condition.
Read more →VRTXLilly, J&J CEOs top pharma’s highest paid list—again
Eli Lilly's David Ricks and Johnson & Johnson's Joaquin Duato topped the list of highest-paid pharma CEOs in 2025, with Ricks earning $36.7 million. Lilly's revenue surged by 45%, while Duato's compensation rose to $32.6 million. Other notable mentions include AbbVie's Robert Michael and Novartis's Vas Narasimhan, both exceeding $30 million in pay. Vertex's CEO Kewalramani and Merck's Davis faced slight decreases in their compensation packages.
Read more →VRTXVertex to Participate in Upcoming May 2026 Investor Conferences
Vertex Pharmaceuticals announced its participation in two upcoming investor conferences in May 2026. The company is known for its innovative therapies for serious diseases and has a strong clinical pipeline. Vertex has been recognized as a top employer, reflecting its commitment to workplace excellence.
Read more →VRTXVertex to Participate in Upcoming May Investor Conferences
Vertex Pharmaceuticals is set to participate in several investor conferences in May. The details regarding the specific conferences and the topics to be discussed have not been disclosed. This participation may provide insights into the company's future plans and developments.
Read more →VRTXVertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
Vertex Pharmaceuticals has secured a reimbursement agreement in Germany for its gene-edited therapy CASGEVY® (exagamglogene autotemcel). This agreement allows eligible patients aged 12 and older with severe sickle cell disease or transfusion-dependent beta thalassemia to access this innovative one-time treatment. This marks a significant advancement in treatment options available in Germany.
Read more →VRTXVertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution
Vertex Pharmaceuticals reported a steady Q1 2026, primarily driven by cystic fibrosis revenues. Analysts view this stability as a precursor to significant developments, particularly with povetacicept, which has shown promising Phase 3 data in treating IgA nephropathy. The company aims to establish a strong renal franchise, potentially rivaling its cystic fibrosis business.
Read more →VRTXVertex Reports First Quarter 2026 Financial Results
Vertex Pharmaceuticals reported strong Q1 2026 financial results with total revenue reaching $2.99 billion, an 8% increase from the previous year. The company highlighted advancements in the Povetacicept program, including the completion of a rolling BLA submission for accelerated approval in IgA nephropathy. Vertex also emphasized ongoing progress in its cystic fibrosis and sickle cell disease portfolios, including notable revenue contributions from its recently launched therapies. The firm reiterated its financial guidance for the full year, anticipating continued growth across its diversified product offerings.
Read more →About Vertex Pharmaceuticals Incorporated
Headquarters50 NORTHERN AVENUE, BOSTON, MA, 02210
BIOPHARMAWATCH ELITE PLUS
Trade the next VRTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime